| + |
dacomitinib | down-regulates 
chemical inhibition
|
ERBB4 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-200908 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 23405260 |
The goal of this study was to compare dacomitinib (pf-00299804), a next generation small molecule tyrosine kinase inhibitor that irreversibly blocks multiple her family receptors (her-1 (egfr), her-2 and her-4 tyrosine kinases), to cetuximab, the current fda approved anti-egfr medication for hnscc and erlotinib, an egfr specific small molecule tyrosine kinase inhibitor. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-205942 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| Other |
|
|
| Publications: |
2 |
Organism: |
Homo Sapiens |
| + |
dacomitinib | down-regulates
chemical inhibition
|
ERBB2 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-200905 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 23405260 |
The goal of this study was to compare dacomitinib (pf-00299804), a next generation small molecule tyrosine kinase inhibitor that irreversibly blocks multiple her family receptors (her-1 (egfr), her-2 and her-4 tyrosine kinases), to cetuximab, the current fda approved anti-egfr medication for hnscc and erlotinib, an egfr specific small molecule tyrosine kinase inhibitor. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-205939 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| Other |
|
|
| Publications: |
2 |
Organism: |
Homo Sapiens |
| + |
dacomitinib | down-regulates
chemical inhibition
|
EGFR |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-205936 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| Other |
|
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-200902 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 23405260 |
The goal of this study was to compare dacomitinib (pf-00299804), a next generation small molecule tyrosine kinase inhibitor that irreversibly blocks multiple her family receptors (her-1 (egfr), her-2 and her-4 tyrosine kinases), to cetuximab, the current fda approved anti-egfr medication for hnscc and erlotinib, an egfr specific small molecule tyrosine kinase inhibitor. |
|
| Publications: |
2 |
Organism: |
Homo Sapiens |
| + |
dacomitinib | down-regulates
chemical inhibition
|
ErbB receptor family |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-269871 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 23405260 |
The goal of this study was to compare dacomitinib (pf-00299804), a next generation small molecule tyrosine kinase inhibitor that irreversibly blocks multiple her family receptors (her-1 (egfr), her-2 and her-4 tyrosine kinases), to cetuximab, the current fda approved anti-egfr medication for hnscc and erlotinib, an egfr specific small molecule tyrosine kinase inhibitor. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
3.0
dacomitinib
